Latest news

Anthracycline exposure in young adults who previously received cancer treatment is associated with a significantly elevated risk for heart failure.

Patients with HER2-positive metastatic breast cancer that is refractory or resistant to trastuzumab emtansine have significantly better outcomes with trastuzumab deruxtecan than a physician’s choice treatment, shows the phase 3 DESTINY-Breast02 trial.

Pregnancy-associated cancers may be linked to an elevated 5-year mortality risk, but the risk varies by tumor site and time of diagnosis, suggests a population-based cohort study.

Research has confirmed that congestive heart failure is significantly more common in people given an anthracycline to treat breast cancer or lymphoma than among those given other types of chemotherapy, even after adjusting for confounding factors.

Anthracycline exposure in young adults who previously received cancer treatment is associated with a significantly elevated risk for heart failure.

A chart review of the Veterans Affairs health system indicates that there are around 14 cases of prostate cancer per year among transgender women.

The 15-year data from the ProtecT trial show low rates of prostate cancer-specific mortality among men with prostate-specific antigen-detected, localized disease regardless of whether they received active monitoring, prostatectomy, or radiotherapy.

Read more about this decision here

A meta-analysis has shown that cutaneous immune-related adverse events are prognostic for improved survival among people with cancer receiving immune checkpoint inhibitor therapy.

Supplementing standard systemic therapy with tumor treating fields prolongs the overall survival of previously treated patients with metastatic NSCLC.